These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 35470996)

  • 1. [A possible relationship between anti-SARS-CoV-2 vaccination and glomerular diseases: food for thought for the nephrologist].
    Rizzo M; Marino A; Sannino A; Urciuoli V; Capuano I; Pisani A
    G Ital Nefrol; 2022 Apr; 39(2):. PubMed ID: 35470996
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Minimal change disease following the Moderna COVID-19 vaccine: first case report.
    Thappy S; Thalappil SR; Abbarh S; Al-Mashdali A; Akhtar M; Alkadi MM
    BMC Nephrol; 2021 Nov; 22(1):376. PubMed ID: 34763669
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glomerular Disease in Temporal Association with SARS-CoV-2 Vaccination: A Series of 29 Cases.
    Caza TN; Cassol CA; Messias N; Hannoudi A; Haun RS; Walker PD; May RM; Seipp RM; Betchick EJ; Amin H; Ziadie MS; Haderlie M; Eduwu-Okwuwa J; Vancea I; Seek M; Elashi EB; Shenoy G; Khalillullah S; Flaxenburg JA; Brandt J; Diamond MJ; Frome A; Kim EH; Schlessinger G; Ulozas E; Weatherspoon JL; Hoerschgen ET; Fabian SL; Bae SY; Iqbal B; Chouhan KK; Karam Z; Henry JT; Larsen CP
    Kidney360; 2021 Nov; 2(11):1770-1780. PubMed ID: 35372991
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sibling cases of gross hematuria and newly diagnosed IgA nephropathy following SARS-CoV-2 vaccination.
    Uchiyama Y; Fukasawa H; Ishino Y; Nakagami D; Kaneko M; Yasuda H; Furuya R
    BMC Nephrol; 2022 Jun; 23(1):216. PubMed ID: 35729514
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IgA nephropathy with glomerular capillary IgA deposition following SARS-CoV-2 mRNA vaccination: a report of three cases.
    Yokote S; Ueda H; Shimizu A; Okabe M; Yamamoto K; Tsuboi N; Yokoo T
    CEN Case Rep; 2022 Nov; 11(4):499-505. PubMed ID: 35562631
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New-onset IgA nephropathy following COVID-19 vaccination.
    Ma Y; Xu G
    QJM; 2023 Feb; 116(1):26-39. PubMed ID: 35920797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New Onset Biopsy-Proven Nephropathies after COVID Vaccination.
    Fenoglio R; Lalloni S; Marchisio M; Oddone V; De Simone E; Del Vecchio G; Sciascia S; Roccatello D
    Am J Nephrol; 2022; 53(4):325-330. PubMed ID: 35354140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential Antibody Response to mRNA COVID-19 Vaccines in Healthy Subjects.
    Wheeler SE; Shurin GV; Yost M; Anderson A; Pinto L; Wells A; Shurin MR
    Microbiol Spectr; 2021 Sep; 9(1):e0034121. PubMed ID: 34346750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Th1 Cytokines Signature in 2 Cases of IgA Nephropathy Flare after mRNA-Based SARS-CoV-2 Vaccine: Exploring the Pathophysiology.
    Martinez Valenzuela L; Oliveras L; Gomà M; Quiros E; Antón-Pámpols P; Gómez-Preciado F; Fulladosa X; Cruzado JM; Torras J; Draibe J
    Nephron; 2022; 146(6):564-572. PubMed ID: 35640535
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
    Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
    Front Immunol; 2021; 12():802858. PubMed ID: 35003131
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunoglobulin A vasculitis post-severe acute respiratory syndrome coronavirus 2 vaccination and review of reported cases.
    Hashizume H; Ajima S; Ishikawa Y
    J Dermatol; 2022 May; 49(5):560-563. PubMed ID: 35229346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New insights into the mucosal immune pathogenesis of IgA nephropathy from the perspective of COVID-19 vaccination.
    Ma Y; Huang Y; Xu G
    QJM; 2023 Mar; 116(3):181-195. PubMed ID: 36592052
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An adolescent girl diagnosed with IgA nephropathy following the first dose of the COVID-19 vaccine.
    Okada M; Kikuchi E; Nagasawa M; Oshiba A; Shimoda M
    CEN Case Rep; 2022 Aug; 11(3):376-379. PubMed ID: 35118635
    [TBL] [Abstract][Full Text] [Related]  

  • 15. mRNA vaccine-induced T cells respond identically to SARS-CoV-2 variants of concern but differ in longevity and homing properties depending on prior infection status.
    Neidleman J; Luo X; McGregor M; Xie G; Murray V; Greene WC; Lee SA; Roan NR
    Elife; 2021 Oct; 10():. PubMed ID: 34636722
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gross hematuria can be an impact of severe acute respiratory syndrome coronavirus 2 vaccination on immunoglobulin A nephropathy: a case report.
    Kanamori H
    J Med Case Rep; 2022 Jul; 16(1):273. PubMed ID: 35818083
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relapse of minimal change disease after inactivated SARS-CoV-2 vaccination: case report.
    Özkan G; Bayrakçı N; Karabağ S; Güzel EÇ; Ulusoy S
    Int Urol Nephrol; 2022 Apr; 54(4):971-972. PubMed ID: 34181144
    [No Abstract]   [Full Text] [Related]  

  • 18. Epidemiology of Immune-Mediated Glomerulopathies before and after SARS-CoV-2 Vaccination: A Tertiary Referral Hospital Experience.
    Zamora JI; López-Martínez M; Patricio Liebana M; Leon Román JC; Bermejo S; Vergara A; Agraz I; Terrades NR; Azancot MA; Toapanta N; Gabaldon MA; Soler MJ
    J Clin Med; 2023 Mar; 12(6):. PubMed ID: 36983419
    [TBL] [Abstract][Full Text] [Related]  

  • 19. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
    Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC
    Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant - National Healthcare Safety Network, March 1-August 1, 2021.
    Nanduri S; Pilishvili T; Derado G; Soe MM; Dollard P; Wu H; Li Q; Bagchi S; Dubendris H; Link-Gelles R; Jernigan JA; Budnitz D; Bell J; Benin A; Shang N; Edwards JR; Verani JR; Schrag SJ
    MMWR Morb Mortal Wkly Rep; 2021 Aug; 70(34):1163-1166. PubMed ID: 34437519
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.